Joseph D. Rosenblatt

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology · 2012 · 979 citations · Full text

B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab

R. John Looney, Jennifer H. Anolik, Debbie Campbell et al. · Arthritis & Rheumatism · 2004 · 772 citations

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · The Lancet Oncology · 2021 · 574 citations

Lymphoid Neoplasia, Axicabtagene Ciloleucel, Medicine +8

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Luis E. Raez, Kyriakos P. Papadopoulos, Alejandro D. Ricart et al. · Cancer Chemotherapy and Pharmacology · 2012 · 509 citations

Oncology, 2-Deoxy-d-glucose Alone, Medicine +8